2024-20550. Medical Devices; Immunology and Microbiology Devices; Classification of the Whole Exome Sequencing Constituent Device
Table 1—Whole Exome Sequencing Constituent Device Risks and Mitigation Measures
Identified risks to health Mitigation measures Inaccurate test results and failure to provide results Certain design verification and validation, including certain analytical studies and clinical studies; and Certain labeling information, including certain performance information and device limitations. Incorrect application or interpretation of results Certain design verification and validation, including certain clinical studies; and Certain labeling information, including certain performance information and device limitations. User error and improper use of the device Certain design verification and validation, including certain analytical studies and clinical studies; and Certain labeling information, including certain performance information and device limitations.
Document Information
- Effective Date:
- 9/11/2024
- Published:
- 09/11/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final amendment; final order.
- Document Number:
- 2024-20550
- Dates:
- This order is effective September 11, 2024. The classification was applicable on December 23, 2020.
- Pages:
- 73565-73568 (4 pages)
- Docket Numbers:
- Docket No. FDA-2024-N-4018
- Topics:
- Biologics, Laboratories, Medical devices
- PDF File:
- 2024-20550.pdf
- CFR: (1)
- 21 CFR 866